NUSANO APPOINTS INDUSTRY EXPERT ALEXANDRE GIBIM AS CHIEF OPERATIONS OFFICER
EXECUTIVE WITH THREE DECADES OF SUCCESSFUL MULTINATIONAL OPERATIONS AND COMMERCIAL EXPERIENCE TO LEAD LAUNCH OF PROPRIETARY RADIOISOTOPE PRODUCTION PLATFORM […]
About:Press Release
Posts by Press Release :
BioUtah Participates in American Cancer Society Policy Panel Presentation
Kelvyn Cullimore, BioUtah’s CEO, participated as a panelist. […]
Merit Medical Launches the Aspira® Evacuated Drainage Bottle
Advanced design complements comprehensive drainage portfolio, expanding compassionate at-home treatment options to more patients […]
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent Clostridioides difficile infection in 2024. […]
New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women
Nearly three out of four women falsely believe a pap smear will reveal ovarian cancer presence […]
Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work
Myriad Genetics announced Great Place To Work® and Fortune magazine have named Myriad Genetics to the 2023 Fortune Best Workplaces in Health Care™ List.
[…]
Ultradent Named a Fortune Magazine Top Workplace for Third Straight Year
Ultradent Products is being recognized for the third consecutive year as a Fortune Magazine Top Large Workplace in Manufacturing and Production. […]
BioTuesdays Features Halia Therapeutics CEO
In a recent interview with BioTuesdays, Halia and Co-Founder David Bearss, P.HD., said that the company is “growing to become a leader in targeting the NLRP3 inflammasome through a unique mechanism of action.” Closely-held Halia Therapeutics is developing a broad pipeline of novel therapies that are essential mediators of immune cell signaling with the potential […]
BlueWind Medical’s Revi™ System Secures U.S. FDA De Novo Classification Grant for the Treatment of Urgency Incontinence
Revi redefines the treatment of Urgency Incontinence with a patient-centric implantable tibial neuromodulation solution that empowers patients […]
Inherent Biosciences, Inc. Advances Fertility Solutions With Transformative Grant Funding From the NIH
A Leap Forward for Patients, a Promising Opportunity for Investors, and a Revolutionary Tool for Physicians […]
This plan to cut drug prices could result in lost jobs and fewer medicines
By Kelvyn Cullimore For the Deseret News […]
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 […]